MCID: OVR034
MIFTS: 36

Ovarian Clear Cell Adenocarcinoma malady

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Ovarian Clear Cell Adenocarcinoma

Aliases & Descriptions for Ovarian Clear Cell Adenocarcinoma:

Name: Ovarian Clear Cell Adenocarcinoma 12 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:5304
NCIt 47 C40078
UMLS 69 C1518693

Summaries for Ovarian Clear Cell Adenocarcinoma

MalaCards based summary : Ovarian Clear Cell Adenocarcinoma is related to clear cell adenocarcinoma of ovary and adenocarcinoma. An important gene associated with Ovarian Clear Cell Adenocarcinoma is ARID1A (AT-Rich Interaction Domain 1A), and among its related pathways/superpathways are MicroRNAs in cancer and Prolactin Signaling Pathway. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include ovary, and related phenotypes are cardiovascular system and endocrine/exocrine gland

Related Diseases for Ovarian Clear Cell Adenocarcinoma

Graphical network of the top 20 diseases related to Ovarian Clear Cell Adenocarcinoma:



Diseases related to Ovarian Clear Cell Adenocarcinoma

Symptoms & Phenotypes for Ovarian Clear Cell Adenocarcinoma

MGI Mouse Phenotypes related to Ovarian Clear Cell Adenocarcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.63 ARID1A ESR2 MTOR PIK3CA SMAD3 STMN1
2 endocrine/exocrine gland MP:0005379 9.43 ARID1A ESR2 HNF1B MTOR PIK3CA SMAD3
3 muscle MP:0005369 9.1 ARID1A ESR2 HNF1B MTOR PIK3CA STMN1

Drugs & Therapeutics for Ovarian Clear Cell Adenocarcinoma

Drugs for Ovarian Clear Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 152)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
4
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
5
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
6
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
9
Mechlorethamine Approved Phase 3,Phase 2,Phase 1 51-75-2 4033
10
Topotecan Approved, Investigational Phase 2, Phase 3,Phase 1 119413-54-6, 123948-87-8 60700
11
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
12
Gemcitabine Approved Phase 3,Phase 2 95058-81-4 60750
13
Olaparib Approved Phase 3,Phase 2 763113-22-0 23725625
14
Succinylcholine Approved Phase 3,Phase 2,Phase 1 306-40-1 5314
15
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
17
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
18
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
19
Cediranib Investigational Phase 3,Phase 2 288383-20-0 9933475
20
Maleic acid Experimental Phase 3,Phase 2 110-16-7 444266
21 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
22 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
23 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
24 Antimitotic Agents Phase 3,Phase 2,Phase 1
25 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
26 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
27 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
28 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
29 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
30 Antibodies Phase 3,Phase 2,Phase 1
31 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
32 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
33 Immunoglobulin G Phase 3,Phase 2,Phase 1
34 Immunoglobulins Phase 3,Phase 2,Phase 1
35 Mitogens Phase 3,Phase 2,Phase 1
36 Adjuvants, Anesthesia Phase 3
37 Analgesics Phase 3,Phase 1
38 Analgesics, Opioid Phase 3
39 Anesthetics Phase 3
40 Anesthetics, General Phase 3
41 Anesthetics, Intravenous Phase 3
42 Central Nervous System Depressants Phase 3
43 Liver Extracts Phase 3,Phase 1,Phase 2
44 Narcotics Phase 3
45 pancreatic polypeptide Phase 3
46 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
47 Alkylating Agents Phase 3,Phase 2,Phase 1
48 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
49 Isophosphamide mustard Phase 3,Phase 2,Phase 1
50 Anti-Infective Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 105)
id Name Status NCT ID Phase
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3
2 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3
3 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3
4 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3
5 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3
6 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3
7 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3
8 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
9 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3
10 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3
11 Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02446600 Phase 3
12 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
13 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3
14 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT00565851 Phase 3
15 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3
16 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3
17 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3
18 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Not yet recruiting NCT02839707 Phase 2, Phase 3
19 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3
20 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3
21 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
22 Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Unknown status NCT01824615 Phase 2
23 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2
24 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Completed NCT01196429 Phase 2
25 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2
26 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2
27 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2
28 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
29 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00003944 Phase 2
30 Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2
31 S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer Completed NCT00008138 Phase 2
32 TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00022347 Phase 2
33 Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers Completed NCT00002538 Phase 2
34 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT01210222 Phase 2
35 High-dose ICE With Amifostine Completed NCT00003657 Phase 2
36 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2
37 A Study of ENMD-2076 in Ovarian Clear Cell Cancers Recruiting NCT01914510 Phase 2
38 Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Recruiting NCT02866370 Phase 2
39 Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02853318 Phase 2
40 Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02713386 Phase 1, Phase 2
41 MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
42 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02101775 Phase 2
43 Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02122185 Phase 2
44 MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Recruiting NCT02364713 Phase 2
45 Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Recruiting NCT00492778 Phase 2
46 Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Recruiting NCT01935934 Phase 2
47 Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers Recruiting NCT01631552 Phase 1, Phase 2
48 Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer Active, not recruiting NCT00979992 Phase 2
49 Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02315430 Phase 2
50 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00888615 Phase 2

Search NIH Clinical Center for Ovarian Clear Cell Adenocarcinoma

Genetic Tests for Ovarian Clear Cell Adenocarcinoma

Anatomical Context for Ovarian Clear Cell Adenocarcinoma

MalaCards organs/tissues related to Ovarian Clear Cell Adenocarcinoma:

39
Ovary

Publications for Ovarian Clear Cell Adenocarcinoma

Articles related to Ovarian Clear Cell Adenocarcinoma:

(show top 50) (show all 84)
id Title Authors Year
1
Vesical clear cell adenocarcinoma arising from endometriosis: A mullerian tumor, indistinguishable from ovarian clear cell adenocarcinoma. ( 27660815 )
2016
2
Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma. ( 25658832 )
2015
3
Splenic metastasis of ovarian clear cell adenocarcinoma: A case report and review of the literature. ( 24669262 )
2014
4
Defect of tropomyosin-related kinase B isotype expression in ovarian clear cell adenocarcinoma. ( 24815386 )
2014
5
Napsin A is a specific marker for ovarian clear cell adenocarcinoma. ( 24721826 )
2014
6
Mass Spectrometric Analysis of the Phosphorylation Levels of the SWI/SNF Chromatin Remodeling/Tumor Suppressor Proteins ARID1A and Brg1 in Ovarian Clear Cell Adenocarcinoma Cell Lines. ( 25083560 )
2014
7
Non-diethylstilbestrol exposed vaginal clear cell adenocarcinoma has a common molecular profile with ovarian clear cell adenocarcinoma: A case report. ( 26082939 )
2014
8
Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma simulating fetal gut in a postmenopausal woman. ( 24707459 )
2014
9
Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice. ( 25398420 )
2014
10
Maximum standardized uptake value of fluorodeoxyglucose positron emission tomography/computed tomography is a prognostic factor in ovarian clear cell adenocarcinoma. ( 24987918 )
2014
11
Patterns of recurrence and role of pelvic radiotherapy in ovarian clear cell adenocarcinoma. ( 25275661 )
2014
12
Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. ( 24504419 )
2014
13
Expression of chromobox homolog 7 (CBX7) is associated with poor prognosis in ovarian clear cell adenocarcinoma via TRAIL-induced apoptotic pathway regulation. ( 24375438 )
2013
14
Annexin A4 is involved in proliferation, chemo-resistance and migration and invasion in ovarian clear cell adenocarcinoma cells. ( 24244679 )
2013
15
Stathmin Regulates Hypoxia-Inducible Factor-1I+ Expression through the Mammalian Target of Rapamycin Pathway in Ovarian Clear Cell Adenocarcinoma. ( 23819061 )
2013
16
Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene. ( 23430509 )
2013
17
Secretome-based identification of TFPI2, a novel serum biomarker for detection of ovarian clear cell adenocarcinoma. ( 23805888 )
2013
18
Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis. ( 23469222 )
2013
19
A recurrence-predicting prognostic factor for patients with ovarian clear-cell adenocarcinoma at reproductive age. ( 24306200 )
2013
20
Integrative analysis of copy number alteration and gene expression profiling in ovarian clear cell adenocarcinoma. ( 23726144 )
2013
21
Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial. ( 23899586 )
2013
22
Two cases of ovarian clear cell adenocarcinoma producing estradiol. ( 22360511 )
2012
23
PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. ( 22120431 )
2012
24
ACTN4 gene amplification and actinin-4 protein overexpression drive tumour development and histological progression in a high-grade subset of ovarian clear-cell adenocarcinomas. ( 22348389 )
2012
25
Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas. ( 21983935 )
2012
26
Histological grading of ovarian clear cell adenocarcinoma: proposal for a simple and reproducible grouping system based on tumor growth architecture. ( 22317866 )
2012
27
Promoter methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma. ( 22871047 )
2012
28
Aberrant expression of the mammalian target of rapamycin, hypoxia-inducible factor-1I+, and glucose transporter 1 in the development of ovarian clear-cell adenocarcinoma. ( 22498943 )
2012
29
Biological significance of plasminogen activator inhibitor-1 expression in ovarian clear cell adenocarcinoma. ( 22335020 )
2011
30
Wild-type p53 enhances annexin IV gene expression in ovarian clear cell adenocarcinoma. ( 21348943 )
2011
31
PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. ( 21735444 )
2011
32
Analysis of mTOR inhibition-involved pathway in ovarian clear cell adenocarcinoma. ( 21614172 )
2011
33
Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient. ( 21478826 )
2011
34
Re-expression of estrogen receptor I^ inhibits the proliferation and migration of ovarian clear cell adenocarcinoma cells. ( 21874257 )
2011
35
Validation of the histologic grading for ovarian clear cell adenocarcinoma: a retrospective multi-institutional study by the Japan Clear Cell Carcinoma Study Group. ( 21293288 )
2011
36
Clear cell adenocarcinoma with a component of poorly differentiated histology: a poor prognostic subgroup of ovarian clear cell adenocarcinoma. ( 21804390 )
2011
37
IGFBP-1 is expressed specifically in ovarian clear cell adenocarcinoma. ( 21457161 )
2011
38
Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinoma. ( 20486992 )
2010
39
Cumulative alterations of p27-related cell-cycle regulators in the development of endometriosis-associated ovarian clear cell adenocarcinoma. ( 20546339 )
2010
40
Prognostic and predictive values of E-cadherin for patients of ovarian clear cell adenocarcinoma. ( 21119364 )
2010
41
PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas. ( 19007975 )
2009
42
Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma. ( 19121088 )
2009
43
Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma. ( 19228748 )
2009
44
HOXA10 is overexpressed in human ovarian clear cell adenocarcinoma and correlates with poor survival. ( 20009888 )
2009
45
Glutathione peroxidase 3 is a candidate mechanism of anticancer drug resistance of ovarian clear cell adenocarcinoma. ( 19020706 )
2008
46
Obstructive uropathy as a major presentation of ovarian clear cell adenocarcinoma. ( 18400599 )
2008
47
Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma. ( 18081793 )
2008
48
A synthetic retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), plus cisplatin: potential new therapy for ovarian clear cell adenocarcinoma. ( 18048092 )
2008
49
Ovarian clear cell adenocarcinoma producing alpha-fetoprotein: case report. ( 17624099 )
2007
50
Specific expression of hepatocyte nuclear factor-1beta in the ovarian clear cell adenocarcinoma and its application to cytological diagnosis. ( 17270029 )
2007

Variations for Ovarian Clear Cell Adenocarcinoma

Expression for Ovarian Clear Cell Adenocarcinoma

Search GEO for disease gene expression data for Ovarian Clear Cell Adenocarcinoma.

Pathways for Ovarian Clear Cell Adenocarcinoma

GO Terms for Ovarian Clear Cell Adenocarcinoma

Cellular components related to Ovarian Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol 3-kinase complex GO:0005942 8.62 MTOR PIK3CA

Biological processes related to Ovarian Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription from RNA polymerase II promoter GO:0000122 9.78 ARID1A ESR2 HNF1B SMAD3
2 positive regulation of transcription, DNA-templated GO:0045893 9.62 ARID1A ESR2 HNF1B SMAD3
3 cardiac muscle contraction GO:0060048 9.52 MTOR PIK3CA
4 positive regulation of stress fiber assembly GO:0051496 9.51 MTOR SMAD3
5 positive regulation of nitric oxide biosynthetic process GO:0045429 9.49 MTOR SMAD3
6 positive regulation of epithelial to mesenchymal transition GO:0010718 9.46 MTOR SMAD3
7 gastrulation GO:0007369 9.43 ARID1A SMAD3
8 mitotic spindle organization GO:0007052 9.4 MAP4 STMN1
9 endoderm development GO:0007492 9.37 HNF1B SMAD3
10 intracellular estrogen receptor signaling pathway GO:0030520 9.26 ARID1A ESR2
11 negative regulation of macroautophagy GO:0016242 9.16 MTOR PIK3CA
12 anoikis GO:0043276 8.96 MTOR PIK3CA
13 liver development GO:0001889 8.8 HNF1B PIK3CA SMAD3

Molecular functions related to Ovarian Clear Cell Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.61 ARID1A ESR2 HNF1B MAP4 MTOR PIK3CA
2 tubulin binding GO:0015631 8.62 MAP4 STMN1

Sources for Ovarian Clear Cell Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....